In a letter to Senators, the daughter of JFK urged them to reject her cousin’s bid to be Donald Trump’s health secretary.

CG Oncology, Inc. is an Irvine, California based late-clinical ... two as a monotherapy and one in combination with Merck’s (MRK) Keytruda. CG was formed in 2010 and went public in January ...

Purpose This study aimed to evaluate the specificity of commonly used cluster criteria for defining the presence of glaucomatous visual field abnormalities and the impact of variations in the ...

What Moore’s colleagues say: “Jeff’s efforts in protein engineering and biocatalysis have had an enormous impact on the practice of green chemistry at Merck and beyond ... Borovik, University of ...

McDermott PhD (Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA); Tahseen Mozaffar MD (Division of Neuromuscular Disorders, University ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...

Merck MRK-9.07%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...